What is the recommended management of an acute pulmonary arterial hypertension (PAH) crisis in a pediatric patient?

Management of Pediatric PAH Crisis

In a pediatric PAH crisis, immediately optimize oxygenation and ventilation to avoid hypoxia and acidosis, administer inhaled nitric oxide (iNO) as first-line pulmonary vasodilator therapy, and prepare for urgent intravenous epoprostenol if the patient does not rapidly stabilize. 1

Immediate Stabilization Priorities

The pathophysiology of acute PAH crisis centers on acute RV afterload increase leading to RV failure and circulatory collapse. Your therapeutic approach must simultaneously address three critical targets:

1. Optimize RV Preload and Avoid Overload

• Cautiously administer fluids only if the patient is hypovolemic
• Use diuretics if there are signs of RV volume overload (hepatomegaly, elevated jugular venous pressure)
• Avoid aggressive fluid resuscitation - the failing RV cannot accommodate increased preload 1

2. Reduce Pulmonary Vascular Resistance Acutely

First-line pulmonary vasodilator:

• Inhaled nitric oxide (iNO): Start at 20 ppm, can range 5-80 ppm
• Acts immediately with minimal systemic hypotension
• Must be weaned gradually to avoid rebound crisis 1

If iNO unavailable or insufficient response:

• Intravenous epoprostenol: Start at 2 ng/kg/min and uptitrate rapidly
• This is the gold standard for severe PAH with RV failure 2
• Effective pediatric doses typically 40-150 ng/kg/min (average ~80 ng/kg/min) - substantially higher than adult dosing 2
• Half-life is only 2-5 minutes, so any interruption risks catastrophic rebound 2

Alternative inhaled agents if iNO unavailable:

• Inhaled epoprostenol or iloprost can be considered 2
• Less ideal due to longer onset and more systemic effects

3. Maintain Systemic Perfusion and Coronary Blood Flow

Avoid systemic hypotension at all costs:

• The RV requires adequate coronary perfusion pressure to function
• If hypotensive despite pulmonary vasodilators, use vasopressin as first-line systemic vasoconstrictor
• Vasopressin increases systemic vascular resistance without increasing PVR 1
• Avoid pure alpha-agonists if possible as they may worsen RV-arterial coupling

Inotropic support if needed:

• Milrinone (phosphodiesterase-3 inhibitor): provides both inotropy and pulmonary vasodilation
• Dobutamine: alternative inotrope but may cause tachycardia
• Use cautiously as they can worsen systemic hypotension 1

Critical Supportive Measures

Ventilation strategy:

• Avoid hypoxia (maintain SpO2 >92%), hypercarbia, and acidosis - all potently increase PVR 2, 1
• If mechanically ventilated: minimize peak inspiratory pressures, avoid excessive PEEP
• Consider permissive hypercapnia only if pH >7.25
• Sedation and analgesia are essential to prevent agitation-induced PVR spikes 1

Correct metabolic derangements:

• Aggressively treat acidosis with ventilation optimization and bicarbonate if needed
• Maintain normal calcium and magnesium
• Avoid hypothermia

Escalation for Refractory Crisis

If the patient fails to stabilize with maximal medical therapy:

1. ECMO (extracorporeal membrane oxygenation) should be considered early as bridge-to-recovery or bridge-to-transplant 3, 1

   • VA-ECMO provides both cardiac and respiratory support
   • Allows RV rest and recovery while maintaining systemic perfusion

2. Atrial septostomy may be considered in select cases to decompress the RV and maintain cardiac output, though this is typically a semi-elective procedure rather than acute crisis intervention 3

3. Urgent lung transplantation evaluation if on maximal therapy with progressive deterioration 2

Common Pitfalls to Avoid

• Never abruptly discontinue iNO or intravenous prostacyclins - causes life-threatening rebound PH crisis
• Avoid calcium channel blockers in acute crisis - they have negative inotropic effects and are contraindicated in RV dysfunction 2
• Do not use verapamil - specifically contraindicated in PAH due to negative inotropy and bradycardia 2
• Avoid excessive positive pressure ventilation - worsens RV afterload
• Do not delay ECMO consideration - earlier initiation improves outcomes in refractory cases 1

Post-Crisis Management

Once stabilized, transition to chronic PAH-targeted therapy based on disease severity. WHO functional class III-IV patients require intravenous/subcutaneous prostacyclin therapy without delay 2. Lower-risk patients can be managed with oral PDE5 inhibitors or endothelin receptor antagonists 2.

The 2015 AHA/ATS guidelines emphasize that intravenous prostacyclin analogs should be initiated without delay for higher-risk PAH patients (Class I, Level of Evidence B) 2, and this population includes those recovering from acute crisis.